Bial-Portela Ca & S.a.

Rita Gusmao De Noronha

Laszlo Erno Kiss

Patricio Manuel Vieira Araujo Soares Da Silva

Jorge Bruno Reis Wahnon

William Maton

Domenico Russo

Carla Patricia Da Costa Pereira Rosa

Carla Patricia Rosa

David Alexander Learmonth

Alexander Beliaev

Patricio Manuel Soares Da Silva

Pedro Nuno Palma

A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

Urea compounds and their use as enzyme inhibitors

Growing community of inventors

S. Mamede do Coronado, Portugal

Rita Gusmao De Noronha